<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420562</url>
  </required_header>
  <id_info>
    <org_study_id>ML7267</org_study_id>
    <nct_id>NCT01420562</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis</brief_title>
  <official_title>Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to calculate pharmacokinetic parameters and to evaluate the trough
      levels of posaconazole reached in patients with different stages of mucositis, due to
      chemotherapy and total body irradiation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Posaconazole plasma levels and area under the curve in patients with different stages of mucositis</measure>
    <time_frame>Day 0 (day of transplantation), day +7, day +14</time_frame>
    <description>Plasma levels of posaconazole will be determined to calculate the area under the curve. These values will be correlated with the stage of mucositis, which will be assessed using citrulline monitoring in plasma. The stage of mucositis will also be assessed using the Daily Oral Mucositis Score (DMS) and Daily Gut Mucositis Score (DGS).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</condition>
  <arm_group>
    <arm_group_label>Posaconazole oral suspension</arm_group_label>
    <description>One group of patients will receive posaconazole oral suspension as prophylactic agent.
Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posaconazole oral tablet</arm_group_label>
    <description>Once the oral tablet is available for adminstration to patients, a second group of patients will receive these tablets as prophylactic agent.
Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.</description>
    <arm_group_label>Posaconazole oral suspension</arm_group_label>
    <arm_group_label>Posaconazole oral tablet</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients on the hematology ward who will receive an allogeneic stem cell transplantation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving allogeneic stem cell transplantation - Treated with prophylactic
             posaconazole: oral suspension (200mg three times daily) or tablet (300mg once daily)
             to prevent invasive fungal infections

        Exclusion Criteria:

          -  Gastroparesis

          -  Vomiting or diarrhea within 2 hours after intake of posaconazole

          -  Concomitant administration of potent inducers of the enzyme UGT1A4:
             carbamazepine,phenytoin, phenobarbital, rifabutin, rifampicin,...

          -  Age under 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Vanstraelen, R.Ph.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of Leuven, Faculty of Pharmacy, division Hospital Pharmacy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Vanstraelen, R.Ph.</last_name>
    <phone>(+32) (0)16342339</phone>
    <email>kim.vanstraelen@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabel Spriet, Pharm.D.</last_name>
    <email>isabel.spriet@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kim Vanstraelen, R.Ph.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Spriet, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludo Willems, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogeneic HSCT</keyword>
  <keyword>posaconazole</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>mucositis</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

